Morning Buzz: Apple (AAPL), uniQure N.V. (QURE), GoPro (GPRO), Atmel (ATML), Alcobra Ltd. (ADHD)

Shares of Apple (AAPL) are higher by 0.41% to $113.92 in early market trading on Monday. The iPhone maker said it is involved in a massive clean-up of its iOS App Store to remove iPhone and iPad programs identified as malicious in the first large-scale attack on the popular mobile software platform.

Cupertino disclosed the effort on Sunday after several cyber security firms reported finding a malicious software dubbed “XcodeGhost” that was embedded in hundreds of legitimate apps. The malware is considered very harmful and dangerous since it can steal login details, open up websites, and read and write data on your clipboard.

uniQure N.V. (QURE) shares surged 6.41% to $35.55 in early trading after the company announced positive topline results from Phase I/II Trial in Sanfilippo B syndrome patients using uniQure’s Novel AAV5-based gene therapy.

The name was raised to $50 at Oppenheimer following the announcement.

Shares of GoPro, Inc. (GPRO) are down $1.64, or 4.67%, at $33.51 following a cautious Barron’s report. The publication says danger lurks as others enter the market for action cameras, and that shares could fall more, to $25.

Atmel Corporation (ATML) is up 12% following this morning’s announcement of a deal to be acquired by Dialog Semiconductor (DLGNF) for $4.6 billion, or $10.42 a share. The acquisition, which is expected to be accretive to Dialog’s underlying earnings in FY 2017, makes Atmel Corp. a global leader in both Power Management and Embedded Processing solutions.

Alcobra Ltd. (ADHD) – The Tel Aviv, Israel-based pharmaceutical company today announced that the FDA has granted Fast Track designation to Metadoxine Extended Release [MDX] for the treatment of Fragile X Syndrome.

“We are pleased that the FDA has recognized the potential of MDX in Fragile X Syndrome and granted Fast Track designation for this indication,” commented Dr. Yaron Daniely, President and CEO of Alcobra. “We look forward to our upcoming meeting with the FDA to determine next steps in advancing the development program for MDX in this area of serious unmet medical need.”

Be the first to comment

Leave a Reply

Your email address will not be published.


*